Answers are grounded in this paper and cite their sources.
The treatment of metastatic colorectal cancer has evolved over the last two decades with the FDA approval of several cytotoxic, biological, and targeted agents. In this paper, we review the impact of sidedness, RAS, BRAF, HER-2, and other immune biomarkers on metastatic colorectal cancer treatment selection and sequencing in both the palliative and curative intent settings.
No takes yet. Share an insight, caveat, or question.
Sandhu et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: